Final Report on Low-Dose Estramustine Phosphate (EMP) Monotherapy and Very Low-Dose EMP Therapy combined with LH-RH Agonist for Previously Untreated Advanced Prostate Cancer
T. Kitamura, M. Suzuki, H. Nishimatsu, T. Kurosaki, Y. Enomoto, H. Fukuhara, H. Kume, T. Takeuchi, L. Miao, H. Jiangang, L. Xiaoqiang · Aktuelle Urologie · 2010 · Heft S 01 · S. S34-S40
Bibliografische Angaben
Zusammenfassung
Abstract PURPOSE: In order to assess the efficacy and toxicity of oral estramustine phosphate (EMP) administration, low-dose EMP monotherapy (study 1) and very low-dose EMP therapy with luteinizing hormone-releasing hormone (LH-RH) agonist (study 2) were conducted in previously untreated prostate cancer and long-term outcomes were compared between the 2 study groups. MATERIALS AND METHODS: Studies 1 and 2 were independently performed beginning in June 1999 and November 2001, respectively. Study 1 was composed of 87 patients including 85 assessable patients. All 108 patients recruited for study 2 were assessable…
